Researchers examine benefits of lateral flow testing for treatment of COVID-19 with regards to the new Paxlovid drug

Lateral flow devices, or lateral flow tests, have played a significant role in helping to identify infectious individuals during the coronavirus disease 2019 (COVID-19) pandemic. They have been key for scaling down restrictions designed to reduce the transmission of the disease, allowing individuals to test regularly and isolate before infecting others, as well as reducing the amount of unnecessary isolation from those who display symptoms similar to those seen in COVID-19, but do not have the disease.

As more treatments for COVID-19 are developed, researchers from Harvard University have been exploring the benefits from different testing schemes with regards to the new Paxlovid drug.

Study: The impact of recurrent rapid test strategies on the effectiveness of at-home…

Continue Reading

News Source: